Corcept Therapeutics | CORT - Sales Revenues


Corcept Therapeutics reported $202.12M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
ANI Pharmaceuticals USD 247.06M 19.25M Dec/2025
Ardelyx USD 125.21M 14.89M Dec/2025
Assertio Holdings USD 29.2M 1.92M Sep/2024
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Canopy Growth CAD 74.54M 7.86M Dec/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
J&J USD 24.1B 500M Mar/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Merck USD 16.4B 880M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Pacira USD 196.87M 17.35M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025